T he efficacy of intravenous alteplase declines over time, and clinical benefits have not been established beyond 4.5 hours after stroke onset. 1 It remains unclear whether intravenous thrombolytics are beneficial in carefully selected patients with ischemic stroke presenting in extended time windows.
Preliminary evidence of safety and potential efficacy in an extended time window was obtained in the DIAS (Desmoteplase in Acute Ischemic Stroke) and DEDAS (Dose Escalation of Desmoteplase in Acute Ischemic Stroke) trials. 2, 3 The DIAS-2 trial did not confirm efficacy, but supported an excellent safety profile with the 90 µg/kg dose. 4 Pooling the data from DIAS, DEDAS, and DIAS-2 suggested that desmoteplase was beneficial for patients with proximal arterial occlusion. 5 These findings provided the rationale for the concomitant DIAS-3, DIAS-4, and DIAS-J studies (Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke) of desmoteplase versus placebo in patients treated 3 to 9 hours after stroke onset. 6, 7 DIAS-J was a randomized phase 2 study that evaluated the safety and tolerability of desmoteplase in Japanese patients. DIAS-3 and DIAS-4 were large multinational phase 3 sister trials assessing the efficacy and safety of 90 µg/kg of desmoteplase in the 3-to 9-hour window; a majority of patients in DIAS-3 were recruited in Asia and Europe, whereas most patients in DIAS-4 were from North and Latin America and Europe.
DIAS-3 reached the preplanned sample size of 492 patients in November 2013 and showed that desmoteplase was as safe as placebo, but without clinical benefit. On receiving the results of DIAS-3, the sponsor terminated the DIAS-4 trial after the enrollment of 270 of planned 400 patients, because the goal of 2 positive trials could not be met. Here, we present the results of DIAS-4 and an exploratory analysis of the pooled DIAS-3, DIAS-4, and DIAS-J patient data using the prespecified primary and secondary end points from DIAS-3 and DIAS-4.
The goal of the pooled analysis is to investigate efficacy and safety of intravenous thrombolysis in the so far largest sample of patients with major cerebral artery occlusions being treated beyond 3 hours. In addition, we explored whether late arterial recanalization may be associated with favorable clinical outcome.
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Methods

Study Design
The DIAS-4 study protocol was identical to that of DIAS-3 and has been described in detail elsewhere. 8 In brief, DIAS-4 was a multinational, randomized, double-blind, parallel-group placebo-controlled phase III study designed and conducted in accordance with the principles of the Declaration of Helsinki. Study sites recruited patients with ischemic stroke within 3 to 9 hours of witnessed symptom onset, between 18 and 85 years of age, with a National Institute of Health Stroke Scale (NIHSS) score of 4 to 24 and occlusion or high-grade stenosis in proximal segments of the middle, anterior, or posterior cerebral arteries (MCA-M1 and MCA-M2, ACA, and PCA) as assessed with computed tomography angiography (CTA) or magnetic resonance angiography (MRA) and corresponding to the acute neurological deficit. Patients were excluded if they had acute ischemic injury exceeding 1 of 3 of the MCA territory, half of the ACA or PCA territory, or intracranial hemorrhage (ICH). We defined acute ischemic injury (ischemic core volume) as x-ray hypoattenuation (hypodensity) within the affected arterial territory on computed tomography (CT) or restricted diffusion (increased signal) on diffusion-weighted imaging (DWI). Patients with a prestroke modified Rankin Scale (mRS) score of >1 were excluded. Details of the informed consent procedure and the inclusion/exclusion criteria are presented in the online-only Data Supplement.
Like in DIAS-3, study sites randomized eligible patients 1:1 to desmoteplase 90 µg/kg or placebo, given as a single intravenous bolus injection. Computer-generated randomization lists with stratification for baseline NIHSS (4-14 or 15-24) and for age (18-65, 66-75, and 76-85 years) were used (online-only Data Supplement).
At baseline and between 12 and 24 hours after study medication administration, patients were imaged with CT or magnetic resonance imaging depending on the preference of the study site. Magnetic resonance imaging included DWI, MRA, T2-fluid attenuation inversion recovery, and gradient echo (T2*) sequences. CT included a nonenhanced CT and CTA, the latter being obligatory at baseline and optional at follow-up. An imaging committee consisting of 4 experienced neuroradiologists (online-only Data Supplement) retrospectively assessed brain and vessel imaging for eligibility (occlusion/ high-grade stenosis) independently from the study sites and blinded to all clinical information except the hemisphere affected. In addition, the committee assessed the MRAs and CTAs using the TIMI scale (Thrombolysis in Myocardial Infarction) with the scores: 0=complete occlusion, 1=near complete occlusion, 2=mild-to-moderate stenosis, and 3=normal open vascular segment. TIMI 0 and 1 was categorized as arterial occlusion and TIMI 2 and 3 as arterial patency or recanalization. The committee also measured the volume (mL) of ischemic injury at baseline and follow-up on CT or DWI using computerized planimetry (Io software, Synarc, or Alice, Parexel).
Safety assessments included mortality at day 90, any ICH, symptomatic ICH (SICH) defined as ICH on imaging resulting in a worsening of ≥4 points on NIHSS, major bleeding other than SICH, symptomatic ischemic edema (defined as brain edema with mass effect on imaging resulting in a worsening of ≥4 points on NIHSS), and other adverse events. An adjudication committee blinded to treatment, evaluated all deaths and neurological worsening by ≥4 NIHSS points and categorized their causes. The primary efficacy end point for DIAS-4 was favorable outcome (mRS, 0-2). Only certified raters assessed mRS ratings by direct examination blinded to treatment allocation.
Key secondary efficacy end points (ordered hierarchically) were decreased in NIHSS by ≥8 points from baseline or an NIHSS score of ≤1 at day 90, and the combination of the dichotomized mRS and the NIHSS response.
The mRS response at day 90 was also analyzed using the ordinal scale (with scores 5 [severe disability] and 6 [death] merged into 1 category).
We also analyzed the primary efficacy end point in the following key subgroups (prespecified for DIAS-4 and assessed by the imaging committee):
1. Patients with core-lesion volume of <25 mL on DWI and <25 mL on CT. 2. Patients with time from stroke onset to treatment ≤7 hours and >7 hours. 3. Patients with TIMI score of 0 to 1 at baseline according imaging committee judgment.
In addition, the recanalization rate was assessed at 12 to 24 hours using CTA or MRA in the subgroup of patients with a baseline vessel TIMI score of 0 or 1.
The DIAS-4 protocol prespecified the following data sets: all patientstreated set-comprising all randomized patients who received study medication (all safety analyses); full-analysis set-all treated patients with at least 1 postbaseline measurement of mRS, and the per-protocol set-all full-analysis set patients fulfilling predefined inclusion/exclusion criteria in retrospect ( Table I in 
the online-only Data Supplement).
Like in DIAS-3, we calculated the required sample size using a power of 80% and a 2-sided significance level of 5%. The original sample size was 302 patients (151 in each group), assuming an effect size of 15 percentage points (40% responders with desmoteplase versus 25% with placebo) based on post hoc analyses of the DEDAS, DIAS, and DIAS-2 trials. [2] [3] [4] [5] The protocol-specified analysis of the primary efficacy end point was performed using a logistic regression model with treatment and geographical region as covariates, and baseline NIHSS score, age, and time from stroke onset to treatment as covariates. In case of missing data on outcome at day 90, the last observation was carried forward when analyzing the full-analysis set Table 2 and per-protocol set. For the primary efficacy end point in prespecified key subgroups of patients with core-lesion volume of <25 mL on DWI or <25 mL on CT and patients with time from stroke onset to treatment ≤7 hours and >7 hours, we used a logistic regression model similar to the primary analysis, including a treatment by imaging modality and treatment by time from stroke interaction factor, respectively. DIAS-J was a phase II dose-escalation study designed to test the safety and tolerability of 2 doses (70 and 90 µg/kg) of desmoteplase in Japanese patients. 7 Only data from patients treated with 90 µg/ kg of desmoteplase or placebo are included in the pooled analyses. The DIAS-J study protocol was identical to those of DIAS-3 and DIAS-4 except that only magnetic resonance imaging at baseline was used and only patients with occlusion/severe stenosis in the proximal MCA (M1 and M2 of MCA) were included in DIAS-J.
. Efficacy Results for Placebo-and DSPA-Treated Patients in DIAS-4 Full-Analysis Data Set
The analysis of pooled data from DIAS-3, DIAS-4, and DIAS-J was not prespecified, but followed the statistical analysis plan of DIAS-3 and DIAS-4. We performed all pooled analyses on the intentto-treat (ITT) analysis set. The worst case was used in case of missing data on outcome at day 90. Tests for heterogeneity between studies were performed in separate models with interaction between study and treatment (and interaction variable if relevant, see below).
Results
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke-4
The study was conducted between February 7, 2009 and October 7, 2014. A total of 270 patients were randomized from 81 hospitals in 17 countries from Europe, North America, Latin and South America, South Africa, and Asia (listed in the onlineonly Data Supplement). Patients were randomly assigned to desmoteplase (n=135) or placebo (n=135). Figure (A) shows the CONSORT (Consolidated Standards of Reporting Trials) diagram, and Table 1 presents the baseline characteristics. Thirteen patients were randomized, but not treated, five patients were treated, but had no valid functional assessment done, leaving 252 for the efficacy analysis. In each of the treatment arms, 67 patients were retrospectively found not to fulfill all inclusion/exclusion criteria leaving 57 patients in the desmoteplase group and 61 patients in the placebo group for the per protocol data set ( Table I in 
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Desmoteplase did not significantly increase the proportion of patients with mRS score of 0 to 2 at day 90 by (absolute difference: 6%, P=0.2290) but increased the recanalization rate at 12 to 24 hours by and absolute difference of 22.8% (P=0.0198). Table 1 presents the baseline characteristics of 795 ITT patients (397 placebo and 398 desmoteplase treated), and Figure (B) shows the CONSORT diagram.
Pooled Analysis
Desmoteplase tended to increase the proportion of patients with mRS score of 0 to 2 at day 90 by an absolute difference of 3.6% (P=0.0786; Table 3 ). There was no statistically significant heterogeneity between the 3 studies for the primary end point (P=0.10 for study×treatment interaction). The treatment effect was similar in patients with ischemic injury volume of <25 mL at baseline and for patients with treatment initiation before and after 7 hours. Treatment with desmoteplase was associated with a higher recanalization rate at 12 to 24 hours (11.1% absolute increase, P=0.0168). The ordinal analysis of the primary end point did not show a treatment response.
Recanalization was associated with favorable outcomes at day 90 (mRS, 0-2) in both the desmoteplase-treated (P<0.0001) and placebo-treated patients (P=0.0004). Recanalization was associated with better outcomes for patients in the desmoteplase group, regardless of whether the patients were treated before or after 7 hours. There was no difference in treatment effect by region or by affected vessel. Table 4 presents the safety analysis showing no significant differences between the treatment groups of all 3 trials and the pooled analysis. In DIAS-4, 15 of 126 (11.9%) of the desmoteplase patients died compared with 18 of 131 (13.7%) placebo patients (hazard ratio, 0.82; 95% confidence interval, 0.41: 1.63; P=0.57). Of these 33 patients, 2 of 126 (1.6%) patients died within the first 7 days in the desmoteplase group and 6 of 131 (4.6%) in the placebo group. The SICH rates in DIAS-4 were 3 of 131 (2.3%) in the placebo group and 6 of 126 (4.8%) in the desmoteplase group. In the pooled population, these rates were 10 of 385 (2.6%) and 12 of 382 (3.1%), respectively.
Discussion
Because of early termination, DIAS-4 was underpowered with only 270 patients randomized and did not meet its primary efficacy end point; outcomes in the desmoteplase group were similar to the anticipated outcomes based on the study design projections. Favorable clinical outcomes in the placebo group were, however, more frequent than anticipated (36% versus 25%). In contrast to DIAS-3, patients with small ischemic injury volume on CT, but not on DWI, tended to benefit from desmoteplase. DIAS-4 confirmed that treatment with intravenous 90 µg/kg desmoteplase is safe, despite a median time to the treatment of 7.3 hours. Desmoteplase increased the recanalization rate in the subgroup of patients with confirmed arterial occlusions at baseline and vessel imaging at 24 to 48 hours after randomization. DIAS-4 failed to show a significant effect on clinical outcome, we suspect the primary reasons for this were (1) DIAS-4 was terminated early and, therefore, was underpowered to detect the projected effect of desmoteplase on the primary outcome, (2) the dose of 90 µg/kg was too low to achieve sufficient brain tissue reperfusion in enough subjects to allow significantly better functional recovery, and (3) tissue reperfusion did not result in functional recovery in some patients because of irreversible injury (disappearance of penumbra).
The pooled sample of DIAS-3, DIAS-4, and DIAS-J patients represents the largest pool of ischemic stroke patients with proven major cerebral artery occlusions treated with intravenous thrombolytics between 3 and 9 hours after stroke onset. We did not include the 86 patients treated with 90 µg/ kg of desmoteplase in the earlier DIAS, DEDAS, and DIAS-2 because they had been selected with inclusion/exclusion criteria that differed from the more recent larger studies.
With almost 800 patients, an ITT analysis of the pooled data showed a nonsignificant trend toward a small beneficial effect of desmoteplase on functional outcome. Desmoteplase increased significantly the recanalization rate by absolute difference of 11% in the subgroup described above for DIAS-4, suggesting that 90 µg/kg of desmoteplase had a biological effect on obstructing thrombi leading to reperfusion and potentially improved functional recovery. Interestingly, we observed excellent functional outcomes (mRS, 0-1) in 29% after placebo treatment similar to the 30.6% (357/1166) excellent outcome rate in placebo-treated patients who were randomized after 4.5 hours in the alteplase randomized trials. 1 This confirms that ≈1 of 3 of ischemic stroke patients with small ischemic cores and presumably good collaterals presenting late after stroke onset have excellent long-term outcomes without thrombolysis even if vessel imaging shows a major intracranial artery occlusion. The challenge will remain to identify the 2 of 3 patients who likely will have persistent neurological deficits without treatment. Moreover, our data suggest that late recanalization even beyond 7 hours after stroke onset is closely associated with favorable functional outcome and not with an increased rate of SICH. These results are in line with the recent 5 successful trials of endovascular therapy, where thrombectomy was initiated beyond 3 hours after stroke onset. [9] [10] [11] [12] [13] The statistically significant increase in recanalization rates from an unexpected 38.4% after placebo to 49.5% (desmoteplase) was apparently too small to achieve statistically significant clinical benefits in the late time window. One can speculate that thrombolytic therapy in this type of patienttreatment beyond 3 hours, major artery occlusion, but smallmoderate ischemic lesion-might be beneficial if higher rates of arterial recanalization are achieved compared with the considerable placebo effect, for example, in combination with thrombectomy or by a more potent thrombolytic agent.
In summary, treatment with intravenous 90 µg/kg desmoteplase administered 3 to 9 hours after stroke onset in patients with proven cerebral artery occlusions did not significantly increase favorable clinical outcomes, although it modestly increased arterial recanalization with no increased rate of SICH. Identification of patients with major cerebral artery occlusions • The subject must receive IMP within 60 minutes after completion of diagnostic imaging screening. The time stamp on the last imaging sequence is the reference for calculating the time elapsing.
Main Exclusion Criteria
• The subject has a pre-stroke mRS > 1 indicating previous disability • The subject has previously been exposed to desmoteplase • The subject shows signs of extensive early infarction on MRI or CT in any affected area, that is an infarcted core involving > 1/3 of MCA territory or > 1/2 of the ACA or PCA territories • The subject has imaging evidence of ICH or SAH (regardless of age of the bleeding); AV malformation; cerebral aneurysm; or cerebral neoplasm (incidental meningioma and microbleeds per se are not exclusion criterion. An incidental intracranial aneurysm that is small (< 5 mm), not thrombosed, and not visibly bleeding is not an exclusion criterion • The subject has an internal carotid artery occlusion on the side of the stroke lesion • The subject has been treated with heparin in the past 48 hours and has a prolonged partial thromboplastin time exceeding the upper limit of the local laboratory normal range. Preventive low doses of LMWH (for example, for deep vein thrombosis (DVT) prophylaxis) do not disqualify the subject from the study • The subject is on oral anticoagulants and has a prolonged prothrombin time (INR > 1.6) • The subject has been treated with glycoprotein IIb -IIIa inhibitors within the past 72 hours. Use of single agent oral platelet inhibitors (e.g. low-dose clopidogrel 75 mg or low-dose aspirin ≤325 mg) or the combination of low-dose-aspirin (e.g. 50 mg) and dipyridamole (e.g. 400 mg) prior to study entry is permitted.
Withdrawal Criteria
• A subject must be withdrawn from the study if:
• the subject withdraws his/her consent • the investigator considers it, for safety reasons, in the best interests of the subject that he/she be withdrawn • the subject is lost to follow-up
The date and reason for withdrawal should be noted in the Withdrawal Form in the electronic case report form (eCRF). All subjects who withdraw from the study should, if at all possible, be seen for a Withdrawal Visit scheduled as soon as possible after the subjects withdraw from the study. Subjects, who withdraw from the study, will not be replaced.
Randomization procedures
Patients were randomized in blocks of two. All study personnel and patients were blinded to treatment assignment. In order to be able to allocate patients to study medication in the case of unavailability of the standard randomization procedure (via an interactive voice response system), forced randomization was used.
Details on forced randomization procedures
In order to be able to allocate patients to study medication in the case of unavailability of standard interactive voice response system (IVRS) randomization procedure or delays in the refill of study medication stocks at the sites, forced randomization was used in DIAS-3 and DIAS-4.
If only one type of study medication was available at a site when randomizing a patient, this type of study medication and the corresponding randomization number was automatically allocated to the patient. Consequently, one or more study medication numbers were skipped on the randomization list. These numbers were 'back-filled' and used for the next patient(s) to be randomized (occurred for 17 patients in DIAS-3 and five patients in DIAS-4).
In case the sites experienced problems that precluded them from the usual randomization through the IVRS system, they called a hotline where the site could be instructed to use the study medication with the lowest number available at the site (3 patients in DIAS-3 and 6 patients in DIAS-4).
Both types of forced randomization were considered unbiased by the sponsor, prior to unblinding. As the allocation of treatment still was performed fully blinded, this would not lead to selection bias; the statistical efficacy evaluation (on the FAS) for forced randomized patients was based on the treatment actually received. 
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